Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Settlement With Lilly Paves The Way For Biosimilar Lantus

This article was originally published in The Pink Sheet Daily

Executive Summary

Eli Lilly’s copycat version of Sanofi’s blockbuster insulin Lantus could reach the market in the U.S. in December 2016 following a settlement agreement with Sanofi.

You may also be interested in...



Mylan/Biocon’s Insulin Glargine Has Narrow Window For Approval In US

Thirty-month stay resulting from Sanofi’s patent lawsuit expires on 18 March 2020, two days before Mylan’s application must receive final approval to avoid getting caught in the transition of insulins from drug to biologic regulation. Pre-approval inspection of Biocon’s manufacturing facility resulted in 12 ‘largely procedural’ observations, company says.

Basaglar Saved Medicaid Millions, Highlighting Benefits Of Competition, JAMA Analysis Shows

Researchers analyzed usage rates, market share and reimbursement information for the long-acting insulins Lantus and Basaglar to determine the impact from the launch of Lilly’s long-acting Basaglar.

Lilly/BI's Basaglar: A Rosier Outlook For US Biosimilars?

Sales of the insulin glargine product in its first full year on the market were strong at $432.1m, but Lilly said it is offering steep rebates in exchange for market access and it's not clear that the growth is sustainable if more copies enter the market.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078966

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel